Effects of indinavir in a preliminary phase I study on dogs with stage III slenic hemangiosarcoma

Enrico P. Spugnini, Vincenzo Esposito, Angela M. Groeger, Roberto Cassandro, Nicoletta Onori, Antonio Chirianni, Alfonso Baldi

Research output: Contribution to journalArticlepeer-review

Abstract

HIV protease inhibitors are antiretroviral drugs able to prevent production of infectious particles. It has been shown that these protease inhibitors are able to inhibit cancer-promoted angiogenesis in patients affected by Kaposi's sarcoma. A preliminary phase I study on dogs with stage III splenic hemangiosarcoma was designed in order to evaluate the efficacy and toxicity of the protease inhibitor Indinavir to delay the progression of this advanced neoplasm. The results suggest that Indinavir is potentially beneficial in dogs affected by microscopic residual disease.

Original languageEnglish
Pages (from-to)125-128
Number of pages4
JournalIn Vivo
Volume20
Issue number1
Publication statusPublished - Jan 2006

Keywords

  • Dog
  • Hemagiosarcoma
  • Indinavir

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Effects of indinavir in a preliminary phase I study on dogs with stage III slenic hemangiosarcoma'. Together they form a unique fingerprint.

Cite this